High-Impact Highlights
Treatment with mavacamten led to a 58% reduction in NT-proBNP and a 51% reduction in high-sensitivity cardiac troponin I (hs-cTnI) compared to placebo over 48 weeks.
The decline in cardiac biomarkers occurred early in the treatment course and was maintained throughout the study period, indicating a consistent effect on myocardial physiology.
